The approval is expected to enhance patient access to the battery-powered device. Credit: CHUTTERSNAP on Unsplash.

Synapse Biomedical has received premarket approval (PMA) from the US Food and Drug Administration (FDA) for its NeuRxDiaphragm Pacing System (NeuRx DPS) to treat patients with spinal cord injuries who depend on mechanical ventilation.

The NeuRx DPS battery-powered device is an intramuscular, percutaneous, motor point diaphragm stimulation system.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It offers electrical stimulation through four percutaneous intramuscular electrodes that are implanted directly into the diaphragm using minimally invasive laparoscopy.

Synapse Biomedical CEO and founder Anthony Ignagni said: “Synapse Biomedical is dedicated to helping free people from mechanical ventilators. We are currently stimulating over 10,000,000 breaths per day for spinal cord-injured patients who can’t breathe on their own around the world.

“With this FDA approval, we can make our diaphragm pacer available to many more patients who were previously unable to access a hospital administering our humanitarian device.”

See Also:

The device is suitable for use in patients with stable spinal cord injury (SCI) with stimulable diaphragms, but who don’t have control of their diaphragms.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

NeuRx DPS can be used to help patients aged 18 years and above to breathe without a mechanical ventilator for at least four continuous hours a day.

First implanted in a prospective clinical investigation in 2000, the device has currently benefitted more than 2,500 patients across the world.

The PMA approval enables hospitals to implement the NeuRx DPS system into their standard of care.

In addition, it is expected to enhance patient access to the battery-powered device besides serving as a treatment option in geographical areas that lack an active implant centre.

Early treatment with the NeuRx DPS shortens patient time on mechanical ventilation and decreases hospitalisation time by an average of 19 days, according to data from recent studies.